Abstracts tagged "Infection"

Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…
Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Kenneth G. Saag¹, Kevin L. Winthrop², Daniel E. Furst³, Kimberly Alexander⁴, Angelika Jahreis⁵, Carol Chung⁶ and Kurt Oelke⁷, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³University of California at Los Angeles, Los Angeles, CA, ⁴Epidemiology, Genentech, Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Genentech, Inc, South San Francisco, CA, ⁷Rheumatic Disease Center, Glendale, WI
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Linda T. Hiraki¹, Candace H. Feldman², Mary Beth Son³, Jessica M. Franklin⁴, Michael A. Fischer⁴, Daniel H. Solomon⁵, Seoyoung C. Kim⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
Abstract Number: 531 • 2013 ACR/ARHP Annual Meeting
Influenza Infection Of MHC-I Transgenic Mice Reveals That Erap Is Necessary and Sufficient For Generation Of The B27-Specific Immunodominant Epitope
Ali Akram¹ and Robert Inman², ¹Institute of Medical Science and Department of Immunology, University of Toronto and University Health Network (UHN), Toronto, ON, Canada, ²Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Although HLA-B27 and ERAP are known to confer susceptibility to spondyloarthritis (SpA), the role of these elements in modulating host response to infection is…
Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Kevin L. Winthrop¹, Tanya Momtahen², Stefano Fiore³, Steven P. Weinstein⁴, Janet van Adelsberg⁵, Richard Wu⁶ and Neil Graham⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Program Direction, Sanofi, Bridgewater, NJ, ³Clinical Science, Sanofi, Bridgewater, NJ, ⁴Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁶BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
J. J. Gomez-Reino¹, A. Hazra², C. Fosser², S. Menon³, S. H. Zwillich², R. Riese² and S. Krishnaswami³, ¹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Pfizer Inc, Groton, CT, ³Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 376 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Johanna Bengtsson¹, Pierre Geborek², Tore Saxne³, Martin Englund⁴, Ingemar F. Petersson⁴, Jan-Åke Nilsson⁵, Göran Jönsson⁶ and Meliha C. Kapetanovic⁷, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Lund Universoty, Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, ⁷Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
The risk of pneumococcal infections after immunisation with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patientsBackground/Purpose: The purpose was to examine the risk of…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…
Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Devy Zisman^1,2, Haim Bitterman^1,3, Ilan Feldhamer⁴, Doron Comanesther⁴, Erez Battat⁴, Sari Greenberg-Dotan⁴, Sarit Cohen⁵ and Arnon-Dov Cohen⁴, ¹Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Medical Center, Haifa, Israel
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…
Abstract Number: 2166 • 2013 ACR/ARHP Annual Meeting
Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis
Caroline Y Chang¹, Rika Meyer² and Katherine AB Marzan¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are extremely effective in treating Juvenile Idiopathic Arthritis (JIA). However, TNF-α is critical in immune function, raising concerns of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.